- VANUDIS - Biotech Company
- SkyAngle Building
- Max-Jarecki-Str. 21
- 69115 Heidelberg
- office@vanudis.net
- +49 6221 3919 0
LyNDAL 2.0
Fully human antibodies selected from cancer patient-derived B-cell repertoires
The concept of developing patient-specific phage display antibody libraries derived from B-cell repertoires of tumor-draining lymph nodes ('Lymph Node Derived Antibody Libraries', LYNDAL) was originally developed in the former academic research group of the company’s founders at the NCT Heidelberg (Diebolder et al. 2014, MAbs; doi: 10.4161/mabs.27236).
The LYNDAL concept is based on the idea that antibodies from B-cell repertoires of patients being generated in the course of disease may have unique functional properties that may be exploited for the generation of viable immunotherapeutics. VANUDIS has further developed the concept by creating a next generation lymph node derived antibody phage display library (LyNDAL 2.0). Moreover, a phage display library from antibody producing cells from umbilical cord blood will be employed for selecting antibodies with innate immune system properties for further development into novel pharmaceuticals.